Showing 8801-8810 of 20877 results for "".
Inside the 4 Hits: Targeting APRIL to Change the Course of IgAN
https://reachmd.com/programs/cme/inside-the-4-hits-targeting-april-to-change-the-course-of-igan/48815/Drs. Lafayette, Risk, Suzuki, and Zhang discuss how APRIL fits into the 4-hit hypothesis of IgAN pathogenesis and review emerging disease-modifying therapies.Improving Preventive Care of Patients With Hepatic Encephalopathy: Navigating the Subtleties and Beyond
https://reachmd.com/programs/cme/improving-preventive-care-of-patients-with-hepatic-encephalopathy-navigating-the-subtleties-and-beyond/36305/Learn how PCPs can identify early signs of hepatic encephalopathy to support timely diagnosis and clinical management.Transformative Insights: Latest Evidence for B7-H3 ADCs From WCLC and ESMO 2025
https://reachmd.com/programs/cme/transformative-insights-latest-evidence-for-b7-h3-adcs-from-wclc-and-esmo-2025/36238/Explore recent clinical data on B7-H3 ADCs in ES-SCLC, with expert insights on biological rationale, efficacy outcomes, safety profiles, and patient selection.Current and Emerging Roles of Immunotherapy and ADCs for Patients with Non-Muscle-Invasive and Muscle-Invasive Bladder Cancer
https://reachmd.com/programs/cme/current-and-emerging-roles-of-immunotherapy-and-adcs-for-patients-with-non-muscle-invasive-and-muscle-invasive-bladder-cancer/14553/Are you applying the latest data to your practice? Tune in for expert guidance on using ADCs and immunotherapy to treat your patients with mUC.CELMoDs in Multiple Myeloma: Optimizing RRMM Treatment With Potent Immunomodulatory Drugs
https://reachmd.com/programs/cme/celmods-in-multiple-myeloma-optimizing-rrmm-treatment-with-potent-immunomodulatory-drugs/54459/This program will equip clinicians with a practical understanding of RRMM diagnosis and risk stratification while building familiarity with CELMoDs as an emerging treatment class with the potential to improve outcomes in relapsed/refractory multiple myeloma. Participants will be educated on the highRadiologic Biomarkers in Multiple Sclerosis: Improving Detection and Diagnosis
https://reachmd.com/diseases-diagnoses/ms-immune-disorders/radiologic-biomarkers-in-multiple-sclerosis-improving-detection-and-diagnosis/54604/Imaging biomarkers, including cortical lesions, the central vein sign, and paramagnetic rim lesions, allow for more timely and accurate diagnosis of multiple sclerosis.From Flare to Farewell: The IBD Care Playbook for Advanced Practice Providers
https://reachmd.com/programs/cme/from-flare-to-farewell-the-ibd-care-playbook-for-advanced-practice-providers/39248/Explore IBD from diagnosis to remission with practical cases, treatment strategies, and a treat-to-target approach for optimal patient outcomes.Clearing the Brain Fog: Innovations in the Treatment and Management of Hepatic Encephalopathy
https://reachmd.com/programs/cme/Clearing-the-Brain-Fog-Innovations-in-the-Treatment-and-Management-of-Hepatic-Encephalopathy/39047/Explore diagnostic and treatment challenges in patients with hepatic encephalopathy to improve outcomes for your patients.Valbenazine and Patient-Centered Outcomes in TD: Insights From the KINECT-PRO Study
https://reachmd.com/clinical-practice/psychiatry-and-mental-health/valbenazine-and-patient-centered-outcomes-in-td-insights-from-the-kinect-pro-study/36175/Valbenazine and Patient-Centered Outcomes in TD: Insights From the KINECT-PRO StudyNavigating Pregnancy with Lupus: Understanding Risks and Improving Outcomes
https://reachmd.com/programs/living-rheum/navigating-pregnancy-with-lupus-understanding-risks-and-improving-outcomes/30076/Understanding lupus-related risks in pregnancy is key to improving outcomes and supporting maternal health. Here’s what you should know.